0000000000973056

AUTHOR

Emilio Monte-boquet

0000-0001-5352-2601

showing 2 related works from this author

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemo…

2021

Abstract Introduction Individual pharmacokinetic (PK) profiling in hemophilia A (HA) helps to individualize prophylaxis using population PK models (popPK). A specific popPK model for plasma-derived factor VIII containing von-Willebrand Factor (pdFVIII/VWF) was developed. Aim To compare standard versus PK-driven prophylaxis, using a generic or a specific popPK model for pdFVIII/VWF. Materials and methods A prospective study conducted in HA patients in prophylaxis with pdFVIII/VWF (Fanhdi®) comparing three one-year study periods: (1) standard prophylaxis, (2) PK-guided prophylaxis using a generic pdFVIII popPK model which described FVIII activity irrespective of FVIII concentrate, and (3) PK-…

Adultmedicine.medical_specialtyPopulationHemophilia ABayesian methodPharmacokineticsInternal medicinehemic and lymphatic diseasesvon Willebrand FactorHemarthrosisMedicineHumansPharmacokineticsProspective StudieseducationProspective cohort studyeducation.field_of_studyFactor VIIIbusiness.industryPlasma derivedProphylaxisBayes TheoremHematologyHemarthrosismedicine.diseaseSevere moderateCohortbusinessFactor VIII vWF
researchProduct

Cross‐sectional comparative study of pharmacokinetics and efficacy between sucrose‐formulated recombinant factor VIII (Kogenate ® ) and BAY 81‐8973 (…

2019

Drug compoundingmedicine.medical_specialtyCross-sectional studybusiness.industryTreatment outcomeHematologyGeneral MedicineModerate haemophilia ARecombinant factor viiiPharmacokineticsInternal medicinemedicineIn patientYoung adultbusinessGenetics (clinical)Haemophilia
researchProduct